Equillium (Equillium) Valuation Rank

View and export this data going back to 2018. Start your Free Trial

What is Equillium Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Equillium Valuation Rank Related Terms

Thank you for viewing the detailed overview of Equillium's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (Equillium) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (NAS:EQ) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Executives

Jason A Keyes	officer: Chief Financial Officer	3344 NORTH TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Barbara Troupin	director	C/O EQUILLIUM, INC., 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Christine Zedelmayer	officer: Sr. Vice President and COO	2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Stephen Connelly	director, officer: Chief Scientific Officer	2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Decheng Capital Management Iv (cayman), Llc	10 percent owner	P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Decheng Capital Global Life Sciences Fund Iv, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, P.O. BOX 309, GRAND CAYMAN E9 KY1-1104
Xiangmin Cui	10 percent owner	NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Yu (katherine) Xu	director	P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Joel Rothman	officer: Chief Development Officer	2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Dolca Thomas	officer: Chief Medical Officer	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bala S Manian	director	1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Charles Douglas Mcdermott	director	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Krishna R Polu	officer: Chief Medical Officer	C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Sa Biocon	10 percent owner	CO BDO SA, RUE DE LAVENIR 2, DELEMONT V8 2800
Bruce D. Steel	director, officer: President, CBO	C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555